The company, a spin-out of ETH Zurich and the Paul Scherrer Institute, Switzerland, uses high throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. The company is specialized in GPCR drug discovery and covers hit-generation, hit- to-lead and lead optimization for all targets including orphan GPCRs. InterAx AG has a highly experienced and dedicated team of scientists specialized in AI, mathematical models of signaling pathways, cellular pharmacology and computational chemistry.
|
|
|
|
|
1-10 employees
View all InterAx Biotech employees
|
|
|
Biotechnology Research
|
|
|
PARK innovAARE, Villigen, CH
|
|
|
2016
|
|
|
Drug Discovery, Pharmacology, Ai, Machine Learning, Systems Biology, Gpcr
|
Aurelien Rizk is the CEO of InterAx Biotech. To contact Aurelien Rizk email at [email protected] or [email protected].
The decision makers in InterAx Biotech are Aurelien Rizk, Aurelien Rizk, Gebhard F X Schertler, etc. Click to Find InterAx Biotech decision makers emails.
InterAx Biotech specializes in providing innovative solutions for drug discovery and development. Our services include computational drug design, molecular modeling, and bioinformatics. We leverage advanced algorithms and machine learning techniques to optimize lead compounds and predict their biological activity, thereby accelerating the drug development process.
InterAx Biotech primarily supports the pharmaceutical and biotechnology industries. Our solutions are designed to assist companies in these sectors with their drug discovery efforts, helping them to identify promising candidates more efficiently and reduce the time and cost associated with bringing new therapies to market.
We integrate artificial intelligence and machine learning into our drug discovery processes to enhance predictive modeling and data analysis. By utilizing AI algorithms, we can analyze vast datasets to identify potential drug candidates, predict their interactions with biological targets, and optimize their chemical structures for improved efficacy and safety.
Yes, InterAx Biotech can provide support for regulatory submissions by offering data analysis and documentation services that meet the requirements of regulatory agencies. Our expertise in drug development ensures that our clients have the necessary information and analyses to support their submissions, facilitating a smoother approval process.
To engage our services, potential clients can reach out to us through our website or contact our business development team directly. We typically start with a consultation to understand the client's specific needs and objectives, followed by a proposal outlining our approach, timeline, and pricing. Once an agreement is reached, we initiate the project and maintain regular communication throughout the process.
Absolutely! InterAx Biotech prides itself on offering tailored solutions to meet the unique needs of each client. We understand that every project is different, and we work closely with our clients to develop customized strategies that align with their specific goals, whether it's optimizing a drug candidate or conducting a comprehensive data analysis.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.